BCL2 and neoplasm: Immunohistostaining of tumor sections using anti–Bcl-2 antibodies revealed substantially reduced Bcl-2 immunoreactivity (brown deposits) in pacRNAClv-treated tumors compared with pacRNANClv- and vehicle-treated groups (Fig. 5H).